TINNET as the next step in tinnitus research: Towards evidence-based medicine

The Tinnitus Research Initiative (TRI) has come a long way to bring tinnitus research from several scientific fields together. The European funded TINNET, 'Better Understanding the Heterogeneity of Tinnitus to Improve and Develop New Treatments', can be regarded as the next step. It aims at coordination and standardization in tinnitus research and the enlargement of an already existing database with results from clinical trials. This should lead to a statistically relevant basis for tinnitus research. It promises the opportunity of standardized processes to enable tailor-made assessment for individual patients.

“At the start of the TRI in 2006 as a private initiative, there was only little tinnitus research compared to the number of people suffering from it. This research was isolated and results remained within the separated domains of ENT, audiology, psychology, psychiatry, and etcetera”, Dr. Berthold Langguth, head of the tinnitus center of Regensburg University concludes. TRI had the vision to bring disciplines together and to share results and insights. “Back then”, Langguth remembers, “the general assumption and conclusion were: 'Tinnitus cannot be cured, so learn to live with it'. The people involved in TRI, however, shared the belief that tinnitus should be treatable in principle – for instance with brain stimulation– although this treatment nor any other treatment was not proven yet. Their motto was and still is: 'Together for a cure'.” Since then, a lot has been achieved. For many patients, the suffering from tinnitus has been reduced.

Evidence base

“But tinnitus still is a very heterogeneous illness. It is difficult to treat”, says Langguth, “treatment is for a large part still mainly pioneering, the domain of pilot studies.” As yet, there are no clearly evidence based treatment methods except cognitive behavioral therapy (CBT) – which comes in several forms. Langguth: “But this doesn't affect the tinnitus percept itself, CBT has the goal to facilitate coping with it. While this provides important relief in many cases, it is not yet the solution for every patient suffering from tinnitus. Apart from that, there are many, many approaches with different rationales. Hearing loss compensation, optionally combined with forms of auditory stimulation, is widely accepted, but large controlled studies demonstrating the efficacy of these approaches are needed. Various innovative forms of individualized auditory stimulation offer sounds or music in frequency areas in the neighborhood of the tinnitus frequency. These forms of individualized auditory stimulation can interact with the neuronal mechanisms that generate tinnitus and have shown promising results in pilot studies.” But there is still a lot unclear, Langguth emphasizes: “How large are the clinical effects? Which variant works best with which type(s) of patients? What can we expect from pharmacological treatment or magnetic and electric brain stimulation? Before these newly developed treatments can be implemented in clinical routine, a conclusive statistical basis from large studies would be needed.”

New knowledge

The TINNET initiative was initiated to change this. It has now been approved by the European Cooperation in Science and Technology (COST) Committee of Senior Officials, thus ensuring European funding. “With that, we get the opportunity to lift tinnitus research to the next level. We still largely depend on the outcomes of isolated trials with a couple of dozens of heterogeneous patients, which causes results to partly depend on group configuration. When data from similar trials from dozens of centers or more can henceforth be introduced in the database, this opens a lot of opportunities.” Once detailed data from many persons is gathered, it will allow us to derive new knowledge, says Langguth: “We could understand in more detail what forms of tinnitus do exist and what the differences between the various forms are. The goal would be to create a data-based expert system, which would provide guidance of which treatment has the best chances for success in a given patient: So hopefully in some years, we can ask the database what would be the recommendation for a 56 years old male, who suffers from a tonal tinnitus since a noise trauma two years ago, and the database would tell us, that a combination of drug X and auditory stimulation Y is the most promising first-line treatment for this individual.”

Dr. Berthold Langguth held a speech on the TINNET initiative during the 8th TRI international Conference from 10-13 March in Auckland, New Zealand. COST invites tinnitus researchers from as many European countries as possible to participate in the project.

Leendert van der Ent


Photo: Lasse Designen - Fotolia
L.A. start-up AudioCardio recognised for its neuroplasticity therapy phone app
L.A. start-up AudioCardio recognised for its neuroplasticity therapy phone app

 

apps

© AudioCardio

A start-up mobile app—AudioCardio—designed to boost neuroplasticity and help sufferers of both hearing loss and tinnitus has caught the prize-picking eyes of the US business magazine, Fast Company.

Hearing aid giant Sonova buys headphone firm Sennheiser’s consumer division for €200m
Hearing aid giant Sonova buys headphone firm Sennheiser’s consumer division for €200m

 
 

financial

© Sonova

In a move to boost earnings and expand in the wireless headphones segment, the Swiss hearing device group Sonova, parent of Phonak, is buying the consumer wing of the German headphone and hi-fidelity company, Sennheiser.

Automated Audiometry: An Interview with the Creator of AMTAS, Robert Margolis, PhD
Automated Audiometry: An Interview with the Creator of AMTAS, Robert Margolis, PhD

 

sponsored content

© GSI

As automated audiometry becomes more widespread for busy clinics and teleaudiometry, Grason Stadler Inc. (GSI) interviewed Dr. Robert Margolis to discuss his automated method for testing auditory sensitivity (AMTAS).

Robust health of hearing care market underlined by Demant supremo
Robust health of hearing care market underlined by Demant supremo

 
 

market

© Demant

Accompanying a better-than-expected 2021 revenue forecast by hearing giant Demant, the group’s CEO and President Søren Nielsen has underlined the strength of the hearing health market as it recovers well from the pandemic impact.

EUHA community adds Instagram to its social networking activities
EUHA community adds Instagram to its social networking activities

 

communication

© AWN

The organiser of the world’s biggest audiology event, the European Union of Hearing Aid Acousticians (EUHA), has added Instagram to its Facebook and LinkedIn social network windows.

University of Granada researchers identify genes linked to tinnitus
University of Granada researchers identify genes linked to tinnitus

 

tinnitus

© janiecbros - iStock

Scientists from the University of Granada (UGR) in Spain have made a breakthrough discovery relating genes to tinnitus, specifically genes ANK2, TSC2 and AKAP9 in patients with Meniere’s disease (MD). The work opens the way to new drug treatments.

Hearing aid nostalgia: a video slideshow through hearing device advertising since the 1940s
Hearing aid nostalgia: a video slideshow through hearing device advertising since the 1940s

 

marketing

© Courtesy GN Hearing

A brush through the dust of old hearing aid advertising brings home just how much the past is a foreign country. With the help of the world’s leading hearing device manufacturers, we offer you a slideshow video tour through some classic ads dating back to the 1940s.

Company Directory

New products

GN lines up ten Interton Move hearing aids, including mini rechargeablesGN lines up ten Interton Move hearing aids, including mini rechargeables

 

hearing aids

© GN Hearing

GN Hearing has launched its biggest ever upgrade in the Interton brand: Move is a new range of ten models that its maker markets as high-quality, affordable, and easy to use.

 [ ... ]

Rexton’s new M-Core hearing aid range aimed especially at “essential workers”Rexton’s new M-Core hearing aid range aimed especially at “essential workers”

 
 

hearing aids

© Rexton

The Rexton brand (WS Audiology) has released a new line-up of rechargeable M-Core behind-the-ear (BTE) hearing aids, which includes the M-Core B-Li HP, a device delivering up to 61 hours of battery life on a single charge.

 [ ... ]

Sonova PRISM chip powers new Blu platform from Unitron, emphasising on-the-spot personalisationSonova PRISM chip powers new Blu platform from Unitron, emphasising on-the-spot personalisation

 

hearing aids

© Unitron

Sonova’s Unitron brand has launched a new hearing aid platform—Blu—to offer users a device adaptable to varying daily sound environments.

 [ ... ]